Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal HyperplasiaPRNewsWire • 8h
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • Monday
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive DyskinesiaPRNewsWire • Monday
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi SyndromePRNewsWire • 10/22/26
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's DiseasePRNewsWire • 10/20/26
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal HyperplasiaPRNewsWire • 10/16/26
Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-TermZacks Investment Research • 10/14/26
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-TermZacks Investment Research • 10/13/26
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial ResultsPRNewsWire • 10/12/26
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family ConferencePRNewsWire • 09/30/26
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price HitMarketBeat • 09/23/26
Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/16/26
Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeeking Alpha • 09/10/26
Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha • 09/09/26
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?Zacks Investment Research • 08/31/26
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?Zacks Investment Research • 08/20/26